Efficacy and safety of rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study

BACKGROUND: Rituximab (RTX) is gaining increasing clinical acceptance in the treatment of primary membranous nephropathy (PMN), with demonstrated efficacy and safety. However, there are few clinical studies on RTX for PMN in Asian populations, especially in China. METHODS: To observe and analyse the...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shasha, Huang, Jing, Dong, Jianwei, Li, Zhuo, Sun, Mengyao, Sun, Yujiao, Chen, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175677/
https://www.ncbi.nlm.nih.gov/pubmed/37187749
http://dx.doi.org/10.3389/fimmu.2023.1156470

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175677/
https://www.ncbi.nlm.nih.gov/pubmed/37187749
http://dx.doi.org/10.3389/fimmu.2023.1156470

Ejemplares similares